Highlights Newsletter 2

This newsletter presents you the following key sessions:

1. Real-world data show superior efficacy of Axicabtagene Ciloleucel compared to chemoimmunotherapy in elderly
    patients with relapsed/refractory Large B-Cell Lymphoma after ≥2 lines of prior therapy

2. Efgartigimod safe and effective for primary immune thrombocytopenia

3. Iptacopan resolves anaemia in patients with paroxysmal nocturnal haemoglobinuria

4. Long-term data with more than 6 years of follow-up, solidify the efficacy and safety of acalabrutinib in
    newly-diagnosed CLL patients

5. Sutimlimab improves outcomes in patients with cold agglutinin disease